PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·
K-STREET TRACKER

FOLLOW THE MONEY INTO THE SWAMP

Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.

Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies

💸 Top Spending Clients

🎯 Top Lobbied Tickers

#TickerFilingsTotal $
1META
Meta Platforms Inc.
129$50.2M
2PFE
Pfizer Inc.
87$48.6M
3GM
General Motors Company
103$48.4M
4V
Visa Inc.
46$37.7M
5AMZN
Amazon.com Inc.
80$35.3M
6LMT
Lockheed Martin Corporation
88$29.4M
7FDX
FedEx Corporation
82$28.3M
8LLY
Eli Lilly and Company
83$28.1M
9AMGN
Amgen Inc.
95$28.0M
10MRK
Merck & Co. Inc.
92$27.5M
11AAPL
Apple Inc.
64$26.8M
12GOOGL
Alphabet Inc. Class A
123$26.6M
13MO164$26.2M
14SO
Southern Company
108$26.1M
15UNH
UnitedHealth Group Inc.
67$23.9M
16VZ
Verizon Communications Inc.
116$23.8M
17TMUS159$22.7M
18CHTR137$22.6M
19GD
General Dynamics Corporation
127$22.5M
20T
AT&T Inc.
134$21.6M
21ORCL
Oracle Corporation
132$20.6M
22CMCSA
Comcast Corporation
141$20.4M
23CI
The Cigna Group
64$19.9M
24OXY
Occidental Petroleum Corporation
36$19.9M
25MSFT
Microsoft Corporation
122$19.2M

🆕 Filtered Filings · SAREPTA THERAPEUTICS

clear filters
DateTickerClientRegistrantAmountIssue
2026-04-20SRPTSAREPTA THERAPEUTICSMICHAEL BEST STRATEGIES LLC$110KScientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
2026-04-20SRPTSAREPTA THERAPEUTICSTARPLIN, DOWNS & YOUNG, LLC$90Kfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting
2026-01-20SRPTSAREPTA THERAPEUTICSMICHAEL BEST STRATEGIES LLC$110KScientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
2026-01-20SRPTSAREPTA THERAPEUTICSTARPLIN, DOWNS & YOUNG, LLC$90Kfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting
2025-10-20SRPTSAREPTA THERAPEUTICSMICHAEL BEST STRATEGIES LLC$110KScientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
2025-10-20SRPTSAREPTA THERAPEUTICSTARPLIN, DOWNS & YOUNG, LLC$80Kfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule
2025-07-21SRPTSAREPTA THERAPEUTICSTARPLIN, DOWNS & YOUNG, LLC$80Kfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule
2025-07-21SRPTSAREPTA THERAPEUTICSMICHAEL BEST STRATEGIES LLC$40KRare disease therapeutic development and access Rare disease therapeutic development and access
2025-07-15SRPTSAREPTA THERAPEUTICSMICHAEL BEST STRATEGIES LLC$0Rare disease therapeutic development and access Rare disease therapeutic development and access
2025-04-20SRPTSAREPTA THERAPEUTICSTARPLIN, DOWNS & YOUNG, LLC$80Kfederal budget issues innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule
2025-01-21SRPTSAREPTA THERAPEUTICSTARPLIN, DOWNS & YOUNG, LLC$80KFederal budget issues Innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule